Azazuddin Ahmed

TL;DR: Exenatide plus dapagliflozin was significantly superior to either drug alone for all secondary efficacy endpoints, with greater reductions in fasting plasma and postprandial glucose, more patients with an HbA1c less than 7·0%.

TL;DR: Among patients with type 2 diabetes uncontrolled with metformin, exenatide QW plus dapagliflozin provided sustained improvements in glycemia, weight, and SBP over 52 weeks, with no unexpected safety findings.

TL;DR: The combination of exenatide once weekly plus dapagliflozin reduced cardiovascular risk factors across baseline subgroups for each variable to a greater extent than did either individual drug; the greatest effects were observed in the high baseline sub groups for body weight and SBP.

TL;DR: In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin, fasting plasma glucose,FPG, and 2-h postprandial glucose), weight, and systolic blood pressure than exen atide QW or dapgliflozar alone after 28 weeks of treatment in DURATION-8.

TL;DR: Treatment with exenatide once weekly plus dapagliflozin reduced HbA1c and body weight across all patient subgroups and was more effective than exenate once weekly or dapgliflozar alone in all adequately sized subgroups.